Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tetracycline Hydrochloride

FDA-approved product (suspension, oral), marketed as Achromycin, Achromycin V, Actisite and 12 more.

Registered studies
50+
Lab records
46
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tetracycline Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Burn
  • Duodenal ulcer
  • Eye infection
  • Fever
  • Infection
  • Ornithosis
  • Skin infection
  • Tularemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Tetracycline and derivatives; Tetracyclines; Antibiotics; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01AA07; WHO ATC D06AA04; WHO ATC S01AA09

Repurposing investigation

Tetracycline Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA85.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli87.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae90.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis68.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 25 of 43 lab records
Open Tetracycline Hydrochloride in ChEMBL Registered studies below
Show the 46 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tetracycline Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori

    NCT00712413 · start 2008-08

    Registered record
    Registry ID
    NCT00712413
    Conditions
    Helicobacter Pylori Infection
    Interventions
    OBMT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2008-08
    Completion
    2008-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionOBMT
    PhasePhase 3
    Registry statusWithdrawn

  • Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

    NCT00630396 · start 2008-05

    Registered record
    Registry ID
    NCT00630396
    Conditions
    Stroke, Acute
    Interventions
    Minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2010-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke, Acute
    InterventionMinocycline
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Long-term Safety of Minocycline in Patients With Gum Disease

    NCT00668746 · start 2007-12

    Registered record
    Registry ID
    NCT00668746
    Conditions
    Periodontitis
    Interventions
    Minocycline HCl microspheres
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-12
    Completion
    2009-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis
    InterventionMinocycline HCl microspheres
    PhasePhase 4
    Registry statusCompleted

  • Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer

    NCT00091247 · start 2004-12

    Registered record
    Registry ID
    NCT00091247
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    tetracycline hydrochloride; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-12
    Completion
    2009-07
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventiontetracycline hydrochloride; placebo
    PhaseNot applicable
    Registry statusCompleted

  • Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

    NCT00002682 · start 1995-08-10

    Registered record
    Registry ID
    NCT00002682
    Conditions
    Lymphoma
    Interventions
    Amoxicillin; Bismuth Subsalicylate; Clarithromycin; Metronidazole Hydrochloride; Omeprazole; Tetracycline Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1995-08-10
    Completion
    2001-10-08
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionAmoxicillin; Bismuth Subsalicylate; Clarithromycin; Metronidazole Hydrochloride +2 more
    PhasePhase 2
    Registry statusCompleted